Gastroenterology · Cirrhosis Complications
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Hepatorenal syndrome is a diagnosis of exclusion characterized by progressive renal failure in patients with advanced cirrhosis and ascites.
The underlying pathophysiology involves splanchnic vasodilation leading to systemic hypotension and subsequent renal vasoconstriction.
Urinalysis is typically bland with no significant proteinuria or hematuria; a low urine sodium is characteristic but is not part of the diagnostic criteria and does not reliably separate HRS-AKI from ATN in cirrhosis.
The first-line pharmacological treatment is the combination of intravenous albumin and terlipressin, the only FDA-approved drug for HRS-AKI; norepinephrine (ICU) is an alternative, and midodrine plus octreotide is a less effective option when neither is available.
A fluid challenge with albumin is required to rule out prerenal azotemia before confirming the diagnosis of hepatorenal syndrome.
Hepatorenal syndrome is classified as a functional renal failure because there is no evidence of structural kidney damage on biopsy.
The only definitive treatment and long-term cure for hepatorenal syndrome is liver transplantation.
Vignette unlocked
A 58-year-old male with a history of alcohol-associated cirrhosis presents with increasing abdominal girth and confusion. Physical exam reveals tense ascites, jaundice, and spider angiomata. Laboratory studies show a serum creatinine of 2.4 mg/dL, up from 0.9 mg/dL one week ago. Urinalysis is bland with a urine sodium of 8 mmol/L and no casts. The patient has not received any nephrotoxic agents or diuretics recently.
What is the most appropriate initial pharmacological management for this patient?
Intravenous albumin and terlipressin
The patient's presentation of acute kidney injury in the setting of cirrhosis with a low urine sodium is classic for hepatorenal syndrome, which is managed with vasoconstrictors and albumin to reverse splanchnic vasodilation.
Full handout
High yield triage
Etiology / Epidemiology
Occurs in patients with advanced cirrhosis and ascites due to systemic vasodilation and renal vasoconstriction.
Clinical Manifestations
Presents as azotemia in a cirrhotic patient; a progressive rise in serum creatinine is the defining finding, and HRS-AKI may be non-oliguric.
Diagnosis
Diagnosis of exclusion; AKI by ICA criteria — a rise in serum creatinine ≥0.3 mg/dL within 48 hours or ≥50% from baseline — with no improvement after 2 days of diuretic withdrawal and albumin 1 g/kg/day.
Treatment
First-line vasoconstrictor is terlipressin (FDA-approved in the US since 2022) plus IV albumin; midodrine + octreotide + albumin is an alternative; liver transplant is the only definitive cure.
Prognosis
Extremely poor; median survival is often measured in weeks without transplant.
Full handout
Epidemiology & Etiology
Hepatorenal syndrome (HRS) is a functional renal failure occurring in patients with decompensated cirrhosis. It is frequently precipitated by spontaneous bacterial peritonitis or aggressive diuretic use. It represents a state of extreme splanchnic vasodilation leading to reduced effective arterial blood volume.
Pertinent Anatomy
The pathology centers on the intrarenal (cortical) arterioles and the splanchnic circulation. Systemic vasodilation in the gut leads to a compensatory, yet maladaptive, renal vasoconstriction.
Pathophysiology
Cirrhosis leads to portal hypertension and the release of vasodilators like nitric oxide. This causes systemic hypotension, triggering the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. The resulting intense renal cortical vasoconstriction causes a rapid decline in the glomerular filtration rate despite structurally normal kidneys.
Clinical Manifestations
Patients present with a progressive rise in serum creatinine, with or without oliguria, in the setting of ascites. Red flags include rapid onset of confusion or worsening jaundice. Physical exam often reveals stigmata of chronic liver disease, such as spider angiomata and palmar erythema.
Diagnosis
Diagnosis of HRS-AKI requires a rise in serum creatinine of ≥0.3 mg/dL within 48 hours or ≥50% from baseline, with no improvement after 2 days of diuretic withdrawal and albumin expansion (1g/kg/day); the older fixed >1.5 mg/dL cutoff has been removed. One must rule out acute tubular necrosis (ATN) via urinalysis, which shows a bland sediment in HRS versus muddy-brown granular casts in ATN; FeNa is often below 1% in both in cirrhosis and should not be relied on to separate them.
Treatment
The primary goal is to increase systemic vascular resistance. Terlipressin (FDA-approved in the US since 2022) plus albumin is first-line; Norepinephrine with albumin is an ICU alternative; midodrine plus octreotide with albumin is a less effective option when neither is available. to reverse splanchnic vasodilation. Terlipressin carries a boxed warning for serious or fatal respiratory failure and is contraindicated in hypoxia or worsening respiratory symptoms and in ongoing coronary, peripheral, or mesenteric ischemia. IV albumin is mandatory to maintain oncotic pressure. The only definitive treatment is liver transplantation.
Prognosis
The prognosis is dismal without intervention, with median survival often less than 3 months. Patients require close monitoring of fluid intake/output and electrolytes. HRS is a major predictor of mortality in patients awaiting liver transplant.
Differential Diagnosis
Acute Tubular Necrosis: muddy-brown granular casts (FeNa often below 1% in cirrhosis)
Prerenal Azotemia: Responds rapidly to fluid resuscitation
Acute Interstitial Nephritis: Presence of eosinophiluria and drug exposure
Glomerulonephritis: Presence of hematuria and RBC casts
Obstructive Uropathy: Hydronephrosis on renal ultrasound